Table 3.
Currently commercially available GLP-1 receptor agonists for the treatment of obesity.
| Agent | Category | Type of use | Frequency of use | Indicationa | Commercial names | Doses (mg) |
|---|---|---|---|---|---|---|
| Liraglutide | Single GLP-1 RA | Injectable | Daily | Pediatric and adult | Saxendab, Victozac | 0.6, 1.2, 1.8, 2.4, 3.0 |
| Semaglutide | Single GLP-1 RA | Injectable | Weekly | Pediatric and adult | Wegovyb, Ozempicc | 0.25, 0.5, 1.0, 1.7, 2.4 |
| Tirzepatide | Dual GLP-1/GIP RA | Injectable | Weekly | Adult | Zepboundb, Mounjaroc | 2.5, 5.0, 7.5, 10.0, 12.5, 15.0 |
GLP-1, glucagon-like peptide-1; GIP, glucose-dependent insulinotropic polypeptide; RA, receptor agonist.
a
Approved by FDA.
b
FDA-approved for chronic weight management in patients with obesity or overweight with at least one weight-related condition.
c
FDA-approved for the treatment of type 2 diabetes and approved for chronic weight management in patients with obesity or overweight with at least one weight-related condition, mainly outside the USA.